News on research and diagnostic development for pathogenic diseases.
After nearly a year in development, the firm's rapid antigen test will be submitted by the end of March for a prescription-use claim.
The test is designed to help determine if a patient has an acute respiratory infection and if that infection is bacterial or viral.
The test uses a technology called Switch-Blocker that is co-owned by the companies and enables both viral detection and strain discrimination.
The investment bank said that Lucira's COVID-19 single-use test could have widespread use with potential for adoption in the over-the-counter markets.
The RT-PCR-based test is designed to detect three SARS-CoV-2 genes in saliva samples collected in the presence of a trained observer.
